Sep., 2009       Amphastar Nanjing Pharmaceuticals Inc.incorporated.


Dec., 2010       purchased 48000 sq.m. land as production base.


Feb., 2011       constructed workshop for pilot production and completed validation production successfully.


Apr., 2012       The first API registration file successfully presented to the FDA.


Dec., 2013       To expand production capacity, complete validation batch production .


Jan., 2014       passed the second FDA inspection with no 483First API to get listed on the FDA approval.


Oct., 2015       An advisory committee was convened with a registered capital of $sixty-one million.


Apr., 2016       passed the second FDA inspection with no 483.


Apr., 2017       passed the third inspection of the FDA.


Oct., 2017       "Zero defects" passed the fourth inspection of the FDAConstruction of new district production base broke ground.

© 2020 Amphastar Nanjing Pharmaceuticals Inc. All Rights Reserved.
Master marketing digital